

Seyed-Mohammad Fereshtehnejad

CURRICULUM VITAE

(Updated on 10 November 2017)

1. PERSONAL INFORMATION

1.1 ADDRESS (work)

L7-113, Montreal General Hospital, 1650 Cedar Ave., H3G 1A4 Montreal, QC, Canada
Phone: (+1) 514-934-1934 (ext. 45467)

Karolinska Institutet, Department of neurobiology, care sciences and society (NVS),
Division of Clinical Geriatrics, Novum 5th floor, 14186 Stockholm, Sweden
Phone: +46 (0) 858585472

1.2 CONTACT

Cellphone: (+1) 514-975-1298
E-mail: sm.fereshtehnejad@mail.mcgill.ca
sm.fereshtehnejad@ki.se

2. EDUCATION

Postdoctoral Research Fellowship (Neurodegeneration, Neuroimaging) Montreal Neurological Institute (MNI), McGill University, Montreal, QC, Canada	2016-Present
Doctorate of Philosophy (PhD) (Clinical Neuroscience, Neuroepidemiology) Department of Neurobiology, Care Sciences & Society (NVS), Karolinska Institutet, Stockholm, Sweden	2011-2015
Master of Medical Education (MSc) Faculty of Virtual Education, Tehran University of Medical Sciences, Tehran, Iran	2010-2013
Master of Public Health (MPH) Faculty of Health, Iran University of Medical Sciences, Tehran, Iran	2008-2010
Doctor of Medicine (MD) Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran	2001-2009
Secondary School Diploma in Experimental Sciences Imam Mohammad Bagher High School, Isfahan, Iran	1996-2000

3. LICENSURE

Iranian Medical License by the Ministry of Health and Medical Education of Iran
Issued on: 15 September 2009
No.: 123328

4. CURRENT POSITIONS

1. Postdoctoral Research Fellow, '*Montreal Neurological Institute (MNI), Montreal General Hospital*', McGill University, Montreal, Canada (January 2016-Present)
2. Associated Researcher, '*Department of Neurobiology, Care Sciences and Society (NVS)*', Karolinska Institutet, Stockholm, Sweden (January 2016-Present)

5. WORK EXPERIENCE

5.1 CLINICAL PRACTICE

1. Clinical Internship in '*Rasoul-e-Akram Hospital*', Iran University of Medical Sciences, Tehran, Iran (March 2007- September 2009)

5.2 RESEARCH

1. Postdoctoral Research Fellow, '*Department of Neurobiology, Care Sciences and Society (NVS)*', Karolinska Institutet, Stockholm, Sweden (July 2015-December 2015)
2. Researcher, '*Swedish Dementia Registry (SveDem)*', Karolinska Institutet, Stockholm, Sweden (September 2013- December 2015)
3. Researcher, '*Firoozgar Clinical Research Development Center (FCRDC)*', Iran University of Medical Sciences, Tehran, Iran (April 2010- January 2012)
4. Young Consultant, '*Deputy of Research*', Iran University of Medical Sciences (March 2009- January 2012)
5. Research Fellow, '*Gastroenterology & Hepatology Clinic of Professor Daryani*', Tehran, Iran (October 2007- January 2012)
6. Research Assistant, '*Jondishapour Neurology Clinic*', Tehran, Iran (June 2007- September 2010)

6. RESEARCH INTERESTS

1. Neuroepidemiology
2. Neurodegeneration
3. Neuroimaging
4. Public Health

7. PUBLICATIONS

7.1 BIBLIOMETRIC SUMMARY

- Total Number of Manuscripts: **164** (PUBMED)
- Total Number of First Authorship: **28** (PUBMED)
- Total Number of Citations: **6773** (Google Scholar), **7105** (SCOPUS)
- h-index: **26** (Google Scholar), **20** (SCOPUS)

7.2 ARTICLES PUBLISHED IN PEER-REVIEWED JOURNALS INDEXED IN PUBMED

1. GBD 2015 Neurological Disorders Collaborator Group, ..., **Fereshtehnejad SM**, ..., Vos T. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Neurol.* 2017 Nov;16(11):877-897. doi: 10.1016/S1474-4422(17)30299-5.
2. GBD 2016 Risk Factors Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1345-1422. doi: 10.1016/S0140-6736(17)32366-8.
3. GBD 2016 DALYs and HALE Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1260-1344. doi: 10.1016/S0140-6736(17)32130-X.
4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2.
5. GBD 2016 Causes of Death Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1151-1210. doi: 10.1016/S0140-6736(17)32152-9.
6. GBD 2016 Mortality Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1084-1150. doi: 10.1016/S0140-6736(17)31833-0.
7. GBD 2016 SDG Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1423-1459. doi: 10.1016/S0140-6736(17)32336-X.
8. Abbasi M, Nabavi SM, **Fereshtehnejad SM**, Jou NZ, Ansari I, Shayegannejad V, Mohammadianinejad SE, Farhoudi M, Noorian A, Razazian N, Abedini M, Faraji F. Multiple sclerosis and environmental risk factors: a case-control study in Iran. *Neurol Sci.* 2017 Nov;38(11):1941-1951. doi: 10.1007/s10072-017-3080-9.
9. **Fereshtehnejad SM**, Skogar Ö, Lökk J. Evolution of Orofacial Symptoms and Disease Progression in Idiopathic Parkinson's Disease: Longitudinal Data from the Jönköping Parkinson Registry. *Parkinsons Dis.* 2017;2017:7802819. doi: 10.1155/2017/7802819.
10. GBD 2015 Eastern Mediterranean Region Transportation Injuries Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Transport injuries and deaths in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 Study. *Int J Public Health.* 2017 Aug 3. doi: 10.1007/s00038-017-0987-0

11. GBD 2015 Eastern Mediterranean Region Cancer Collaborators, ..., **Fereshtehnejad SM**, ..., Fitzmaurice C. Burden of cancer in the Eastern Mediterranean Region, 2005-2015: findings from the Global Burden of Disease 2015 Study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-0999-9.
12. GBD 2015 Eastern Mediterranean Region Adolescent Health Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1003-4.
13. GBD 2015 Eastern Mediterranean Region Maternal Mortality Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1004-3.
14. GBD 2015 Eastern Mediterranean Region Intentional Injuries Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Intentional injuries in the Eastern Mediterranean Region, 1990-2015: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1005-2.
15. GBD 2015 Eastern Mediterranean Region Vision Loss Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of vision loss in the Eastern Mediterranean region, 1990-2015: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1000-7.
16. GBD 2015 Eastern Mediterranean Region HIV/AIDS Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990-2015: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1023-0.
17. GBD 2015 Eastern Mediterranean Region Mental Health Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. The burden of mental disorders in the Eastern Mediterranean region, 1990-2015: findings from the global burden of disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1006-1.
18. GBD 2015 Eastern Mediterranean Region LRI Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of lower respiratory infections in the Eastern Mediterranean Region between 1990 and 2015: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1007-0.
19. GBD 2015 Eastern Mediterranean Region Cardiovascular Disease Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990-2015: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1012-3.
20. GBD 2015 Eastern Mediterranean Region Obesity Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of obesity in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1002-5.
21. GBD 2015 Eastern Mediterranean Region Neonatal, Infant, and under-5 Mortality Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the

- Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-0998-x.
22. GBD 2015 Eastern Mediterranean Region Diabetes and CKD Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1014-1.
 23. GBD 2015 Eastern Mediterranean Region Diarrhea Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of diarrhea in the Eastern Mediterranean Region, 1990-2015: Findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1008-z.
 24. GBD 2015 Eastern Mediterranean Region Collaborators, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Danger ahead: the burden of diseases, injuries, and risk factors in the Eastern Mediterranean Region, 1990-2015. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1017-y.
 25. Karimkhani C, ..., **Fereshtehnejad SM**, ..., Naghavi M. Burden of Skin and Subcutaneous Diseases in Iran and Neighboring Countries: Results from the Global Burden of Disease Study 2015. *Arch Iran Med*. 2017 Jul;20(7):429-440.
 26. Moradi-Lakeh M, ..., **Fereshtehnejad SM**, ..., Naghavi M. Trend of Socio-Demographic Index and Mortality Estimates in Iran and its Neighbors, 1990-2015; Findings of the Global Burden of Diseases 2015 Study. *Arch Iran Med*. 2017 Jul;20(7):419-428.
 27. Sepanlou SG, ..., **Fereshtehnejad SM**, ..., Malekzadeh R. Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE) in Iran and its Neighboring Countries, 1990-2015: Findings from Global Burden of Disease Study 2015. *Arch Iran Med*. 2017 Jul;20(7):403-418.
 28. Djalalinia S, ..., **Fereshtehnejad SM**, ..., Farzadfar F. Prevalence and Years Lived with Disability of 310 Diseases and Injuries in Iran and its Neighboring Countries, 1990-2015: Findings from Global Burden of Disease Study 2015. *Arch Iran Med*. 2017 Jul;20(7):392-402.
 29. **Fereshtehnejad SM**, Garcia-Ptacek S, Religa D, Holmer J, Buhlin K, Eriksdotter M, Sandborgh-Englund G. Dental care utilization in patients with different types of dementia: A longitudinal nationwide study of 58,037 individuals. *Alzheimers Dement*. 2017 Jul 8. pii: S1552-5260(17)30233-9. doi: 10.1016/j.jalz.2017.05.004.
 30. Secnik J, Cermakova P, **Fereshtehnejad SM**, Dannberg P, Johnell K, Fastbom J, Winblad B, Eriksdotter M, Religa D. Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry. *Diabetes Care*. 2017 Sep;40(9):1159-1166. doi: 10.2337/dc16-2516.
 31. Shafieesabet A, **Fereshtehnejad SM**, Shafieesabet A, Delbari A, Baradaran HR, Postuma RB, Löck J. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson's disease: A meta-analysis. *Parkinsonism Relat Disord*. 2017 Sep;42:1-11. doi: 10.1016/j.parkreldis.2017.06.006.
 32. **Fereshtehnejad SM**, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. *Brain*. 2017 Jul 1;140(7):1959-1976. doi: 10.1093/brain/awx118.

33. GBD 2015 Healthcare Access and Quality Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet*. 2017 Jul 15;390(10091):231-266. doi: 10.1016/S0140-6736(17)30818-8.
34. **Fereshtehnejad SM**, Al-Qassabi A, Postuma RB. Sleep Disturbances in the Prodromal Stage of Parkinson Disease. *Curr Treat Options Neurol*. 2017 Jun;19(6):22. doi: 10.1007/s11940-017-0458-1.
35. **Fereshtehnejad SM**, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB. Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. *Mov Disord*. 2017 Jun;32(6):865-873. doi: 10.1002/mds.26989.
36. **Fereshtehnejad SM**, Postuma RB. Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression? *Curr Neurol Neurosci Rep*. 2017 Apr;17(4):34. doi: 10.1007/s11910-017-0738-x.
37. Karlstedt M, **Fereshtehnejad SM**, Aarsland D, Lökk J. Determinants of Dyadic Relationship and Its Psychosocial Impact in Patients with Parkinson's Disease and Their Spouses. *Parkinsons Dis*. 2017;2017:4697052. doi: 10.1155/2017/4697052.
38. **Fereshtehnejad SM**, Rahmani A, Shafieesabet M, Soori M, Delbari A, Motamed MR, Lökk J. Prevalence and associated comorbidities of restless legs syndrome (RLS): Data from a large population-based door-to-door survey on 19176 adults in Tehran, Iran. *PLoS One*. 2017 Feb 17;12(2):e0172593. doi: 10.1371/journal.pone.0172593.
39. Moradi-Lakeh M, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: findings from the Global Burden of Disease Study 2013. *Ann Rheum Dis*. 2017 Aug;76(8):1365-1373. doi: 10.1136/annrheumdis-2016-210146.
40. Farhadi F, Vosoughi K, Shahidi GA, Delbari A, Lökk J, **Fereshtehnejad SM**. Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females. *Neuropsychiatr Dis Treat*. 2017 Feb 1;13:329-338. doi: 10.2147/NDT.S124984.
41. Charara R, ..., **Fereshtehnejad SM**, ..., Mokdad AH. The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. *PLoS One*. 2017 Jan 17;12(1):e0169575. doi: 10.1371/journal.pone.0169575.
42. Borghei-Razavi H, Tomio R, **Fereshtehnejad SM**, Shibao S, Schick U, Toda M, Yoshida K, Kawase T. Pathological Location of Cranial Nerves in Petroclival Lesions: How to Avoid Their Injury during Anterior Petrosal Approach. *J Neurol Surg B Skull Base*. 2016 Feb;77(1):6-13. doi: 10.1055/s-0035-1555137.
43. Abbasi M, Nabavi SM, **Fereshtehnejad SM**, Ansari I, Zerafatjou N, Shayegannejad V, Mohammadianinejad SE, Farhoudi M, Noorian A, Razazian N, Abedini M, Faraji F. Risk factors of Multiple sclerosis and their Relation with Disease Severity: A Cross-sectional Study from Iran. *Arch Iran Med*. 2016 Dec;19(12):852-860. doi: 0161912/AIM.007.

44. Khalil I, ..., **Fereshtehnejad SM**, ..., Mokdad AH. Burden of Diarrhea in the Eastern Mediterranean Region, 1990-2013: Findings from the Global Burden of Disease Study 2013. *Am J Trop Med Hyg*. 2016 Dec 7;95(6):1319-1329.
45. Garcia-Ptacek S, Modéer IN, Kåreholt I, **Fereshtehnejad SM**, Farahmand B, Religa D, Eriksdotter M. Differences in diagnostic process, treatment and social support for Alzheimer's dementia between primary and specialist care: results from the Swedish Dementia Registry. *Age Ageing*. 2017 Mar 1;46(2):314-319. doi: 10.1093/ageing/afw189.
46. Karlstedt M, **Fereshtehnejad SM**, Winnberg E, Aarsland D, Lökk J. Psychometric properties of the mutuality scale in Swedish dyads with Parkinson's disease. *Acta Neurol Scand*. 2017 Aug;136(2):122-128. doi: 10.1111/ane.12706.
47. GBD 2015 Maternal Mortality Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2.
48. GBD 2015 Child Mortality Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1725-1774. doi: 10.1016/S0140-6736(16)31575-6.
49. GBD 2015 Risk Factors Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8.
50. GBD 2015 DALYs and HALE Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1603-1658. doi: 10.1016/S0140-6736(16)31460-X.
51. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.
52. GBD 2015 Mortality and Causes of Death Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1.
53. GBD 2015 SDG Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1813-1850. doi: 10.1016/S0140-6736(16)31467-2.

54. Delbari A, Keyghobadi F, Momtaz YA, Keyghobadi F, Akbari R, Kamranian H, Yazdi MS, Tabatabaei SS, **Fereshtehnejad SM**. Sex differences in stroke: a socioeconomic perspective. *Clin Interv Aging*. 2016 Sep 6;11:1207-1212.
55. **Fereshtehnejad SM**. Strategies to maintain quality of life among people with Parkinson's disease: what works? *Neurodegener Dis Manag*. 2016 Oct;6(5):399-415. doi: 10.2217/nmt-2016-0020.
56. Enache D, **Fereshtehnejad SM**, Kåreholt I, Cermakova P, Garcia-Ptacek S, Johnell K, Religa D, Jelic V, Winblad B, Ballard C, Aarsland D, Fastbom J, Eriksdotter M. Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. *Acta Psychiatr Scand*. 2016 Nov;134(5):430-440. doi: 10.1111/acps.12630.
57. Mokdad AH, ..., **Fereshtehnejad SM**, ..., Murray CJ. Health in times of uncertainty in the eastern Mediterranean region, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet Glob Health*. 2016 Oct;4(10):e704-13. doi: 10.1016/S2214-109X(16)30168-1.
58. GBD 2015 HIV Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJL. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. *Lancet HIV*. 2016 Aug;3(8):e361-e387. doi: 10.1016/S2352-3018(16)30087-X.
59. Dormanesh B, Vosoughi K, Akhoundi FH, Mehrpour M, **Fereshtehnejad SM**, Esmaeili S, Sabet AS. Carotid duplex ultrasound and transcranial Doppler findings in commercial divers and pilots. *Neurol Sci*. 2016 Dec;37(12):1911-1916.
60. Shams S, Granberg T, Martola J, Charidimou A, Li X, Shams M, **Fereshtehnejad SM**, Cavallin L, Aspelin P, Wiberg-Kristoffersen M, Wahlund LO. Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment. *J Cereb Blood Flow Metab*. 2017 Mar;37(3):1006-1013. doi: 10.1177/0271678X16649401.
61. Lovas J, **Fereshtehnejad SM**, Cermakova P, Lundberg C, Johansson B, Johansson K, Winblad B, Eriksdotter M, Religa D. Assessment and Reporting of Driving Fitness in Patients with Dementia in Clinical Practice: Data from SveDem, the Swedish Dementia Registry. *J Alzheimers Dis*. 2016 May 5;53(2):631-8. doi: 10.3233/JAD-160254.
62. Tajeddinn W, **Fereshtehnejad SM**, Seed Ahmed M, Yoshitake T, Kehr J, Shahnaz T, Milovanovic M, Behbahani H, Höglund K, Winblad B, Cedazo-Minguez A, Jelic V, Järemo P, Aarsland D. Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. *J Alzheimers Dis*. 2016 May 4;53(2):621-30. doi: 10.3233/JAD-160022.
63. Konijnenberg E, **Fereshtehnejad SM**, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. *Alzheimer Dis Assoc Disord*. 2017 Apr-Jun;31(2):146-151. doi: 10.1097/WAD.000000000000152.
64. Motamed MR, Nasiri F, **Fereshtehnejad SM**, Mehrpour M, Zamani B, Haghi-Ashtiani B, Rohani F. Complicated orolingual angioedema after recombinant tissue plasminogen activator treatment in stroke patients under angiotensin converting enzyme inhibitor: Report of two cases. *Iran J Neurol*. 2015 Oct 7;14(4):225-7.

65. Shams S, Granberg T, Martola J, Li X, Shams M, **Fereshtehnejad SM**, Cavallin L, Aspelin P, Kristoffersen-Wiberg M, Wahlund LO. Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment. *J Cereb Blood Flow Metab*. 2016 Mar;36(3):621-8. doi: 10.1177/0271678X15606141.
66. **Fereshtehnejad SM**, Shafieesabet A, Shafieesabet M, Shahidi GA, Delbari A, Lökk J. Mortality in Iranian Patients with Parkinson's Disease: Cumulative Impact of Cardiovascular Comorbidities as One Major Risk Factor. *Parkinsons Dis*. 2015;2015:834796. doi: 10.1155/2015/834796.
67. Borghesi-Razavi H, Tomio R, **Fereshtehnejad SM**, Shibao S, Schick U, Toda M, Kawase T, Yoshida K. Anterior petrosal approach: The safety of Kawase triangle as an anatomical landmark for anterior petrosectomy in petroclival meningiomas. *Clin Neurol Neurosurg*. 2015 Dec;139:282-7. doi: 10.1016/j.clineuro.2015.10.032.
68. **Fereshtehnejad SM**, Johannsen P, Waldemar G, Eriksdotter M. Dementia Diagnosis, Treatment, and Care in Specialist Clinics in Two Scandinavian Countries: A Data Comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry. *J Alzheimers Dis*. 2015;48(1):229-39. doi: 10.3233/JAD-150144.
69. GBD 2013 Risk Factors Collaborators, Forouzanfar MH, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015 Dec 5;386(10010):2287-323. doi: 10.1016/S0140-6736(15)00128-2.
70. **Fereshtehnejad SM**, Shafieesabet M, Farhadi F, Hadizadeh H, Rahmani A, Naderi N, Khaefpanah D, Shahidi GA, Delbari A, Lökk J. Heterogeneous Determinants of Quality of Life in Different Phenotypes of Parkinson's Disease. *PLoS One*. 2015 Sep 3;10(9):e0137081. doi: 10.1371/journal.pone.0137081.
71. GBD 2013 DALYs and HALE Collaborators, Murray CJ, ..., **Fereshtehnejad SM**, ..., Vos T. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet*. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X.
72. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, ..., **Fereshtehnejad SM**, ..., Naghavi M. The Global Burden of Cancer 2013. *JAMA Oncol*. 2015 Jul;1(4):505-27. doi: 10.1001/jamaoncol.2015.0735.
73. **Fereshtehnejad SM**, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. *JAMA Neurol*. 2015 Aug;72(8):863-73. doi: 10.1001/jamaneurol.2015.0703.
74. Global Burden of Disease Study 2013 Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4.

75. Rios Romenets S, Anang J, **Fereshtehnejad SM**, Pelletier A, Postuma R. Tango for treatment of motor and non-motor manifestations in Parkinson's disease: a randomized control study. *Complement Ther Med*. 2015 Apr;23(2):175-84. doi: 10.1016/j.ctim.2015.01.015.
76. Ghazi L, **Fereshtehnejad SM**, Abbasi Fard S, Sadeghi M, Shahidi GA, Lökk J. Mini Nutritional Assessment (MNA) is Rather a Reliable and Valid Instrument to Assess Nutritional Status in Iranian Healthy Adults and Elderly with a Chronic Disease. *Ecol Food Nutr*. 2015;54(4):342-57. doi: 10.1080/03670244.2014.994743.
77. **Fereshtehnejad SM**, Shafieesabet M, Rahmani A, Delbari A, Lökk J. Medium-to-high prevalence of screening-detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study. *Neuropsychiatr Dis Treat*. 2015 Feb 5;11:321-32. doi: 10.2147/NDT.S77391.
78. Religa D, **Fereshtehnejad SM**, Cermakova P, Edlund AK, Garcia-Ptacek S, Granqvist N, Hallbäck A, Kåwe K, Farahmand B, Kilander L, Mattsson UB, Nägga K, Nordström P, Wijk H, Wimo A, Winblad B, Eriksdotter M. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. *PLoS One*. 2015 Feb 19;10(2):e0116538. doi: 10.1371/journal.pone.0116538.
79. Motamed MR, **Fereshtehnejad SM**, Abbasi M, Sanei M, Abbaslou M, Meysami S. X-ray radiation and the risk of multiple sclerosis: Do the site and dose of exposure matter? *Med J Islam Repub Iran*. 2014 Dec 9;28:145.
80. **Fereshtehnejad SM**, Hadizadeh H, Farhadi F, Shahidi GA, Delbari A, Lökk J. Comparison of the Psychological Symptoms and Disease-Specific Quality of Life between Early- and Typical-Onset Parkinson's Disease Patients. *Parkinsons Dis*. 2014;2014:819260. doi: 10.1155/2014/819260.
81. Cermakova P, Lund LH, **Fereshtehnejad SM**, Johnell K, Winblad B, Dahlström U, Eriksdotter M, Religa D. Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. *Eur J Heart Fail*. 2015 Jun;17(6):612-9. doi: 10.1002/ejhf.222.
82. GBD 2013 Mortality and Causes of Death Collaborators, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2.
83. Shams S, Martola J, Granberg T, Li X, Shams M, **Fereshtehnejad SM**, Cavallin L, Aspelin P, Kristoffersen-Wiberg M, Wahlund LO. Cerebral microbleeds: different prevalence, topography, and risk factors depending on dementia diagnosis—the Karolinska Imaging Dementia Study. *AJNR Am J Neuroradiol*. 2015 Apr;36(4):661-6. doi: 10.3174/ajnr.A4176.
84. **Fereshtehnejad SM**, Damangir S, Cermakova P, Aarsland D, Eriksdotter M, Religa D. Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. *Alzheimers Res Ther*. 2014 Oct 6;6(5-8):65. doi: 10.1186/s13195-014-0065-2.
85. Bahrami E, Bakhti S, **Fereshtehnejad SM**, Parvaresh M, Khani MR. Extra-axial medulloblastoma in cerebello-pontine angle: A report of a rare case with literature review. *Med J Islam Repub Iran*. 2014 Jul 13;28:57.

86. Eftekharsadat B, Ahadi T, Raissi GR, Shakoory SK, **Fereshtehnejad SM**. Validity of current electrodiagnostic techniques in the diagnosis of carpal tunnel syndrome. *Med J Islam Repub Iran*. 2014 Jun 14;28:45.
87. **Fereshtehnejad SM**, Shafieesabet M, Rahmani A, Farhadi F, Hadizadeh H, Shahidi GA, Delbari A, Lökk J. A novel 6-item screening questionnaire for Parkinsonism: validation and comparison between different instruments. *Neuroepidemiology*. 2014;43(3-4):178-93. doi: 10.1159/000368167.
88. Falahati F, **Fereshtehnejad SM**, Religa D, Wahlund LO, Westman E, Eriksson M. The use of MRI, CT and lumbar puncture in dementia diagnostics: data from the SveDem Registry. *Dement Geriatr Cogn Disord*. 2015;39(1-2):81-91. doi: 10.1159/000366194.
89. **Fereshtehnejad SM**, Shafieesabet M, Shahidi GA, Delbari A, Lökk J. Restless legs syndrome in patients with Parkinson's disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. *Acta Neurol Scand*. 2015 Apr;131(4):211-8. doi: 10.1111/ane.12307.
90. Mousavi SA, **Fereshtehnejad SM**, Khalili N, Naghavi M, Yahyazadeh H. Arterial blood gas and spirometry parameters affect the length of stay in hospitalized asthmatic patients. *Med J Islam Repub Iran*. 2014 Feb 16;28:4.
91. **Fereshtehnejad SM**, Lökk J. Active aging for individuals with Parkinson's disease: definitions, literature review, and models. *Parkinsons Dis*. 2014;2014:739718. doi: 10.1155/2014/739718.
92. Murray CJ, ..., **Fereshtehnejad SM**, ..., Vos T. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014 Sep 13;384(9947):1005-70. doi: 10.1016/S0140-6736(14)60844-8.
93. Cermakova P, **Fereshtehnejad SM**, Johnell K, Winblad B, Eriksson M, Religa D. Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry. *Alzheimers Res Ther*. 2014 Jun 16;6(3):34. doi: 10.1186/alzrt264.
94. **Fereshtehnejad SM**, Naderi N, Rahmani A, Shahidi GA, Delbari A, Lökk J. Psychometric study of the Persian short-form eight-item Parkinson's disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL). *Health Qual Life Outcomes*. 2014 May 20;12:78. doi: 10.1186/1477-7525-12-78.
95. Faxén-Irving G, **Fereshtehnejad SM**, Falahati F, Cedergren L, Göransson H, Wallman K, García-Ptacek S, Eriksson M, Religa D. Body Mass Index in Different Dementia Disorders: Results from the Swedish Dementia Quality Registry (SveDem). *Dement Geriatr Cogn Dis Extra*. 2014 Apr 3;4(1):65-75. doi: 10.1159/000360415.
96. **Fereshtehnejad SM**, Farhadi F, Hadizadeh H, Shahidi GA, Delbari A, Lökk J. Cross-cultural validity, reliability, and psychometric properties of the Persian version of the scales for outcomes in Parkinson's disease-psychosocial questionnaire. *Neurol Res Int*. 2014;2014:260684. doi: 10.1155/2014/260684.
97. Kassebaum NJ, ..., **Fereshtehnejad SM**, ..., Lozano R. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global

- Burden of Disease Study 2013. *Lancet*. 2014 Sep 13;384(9947):980-1004. doi: 10.1016/S0140-6736(14)60696-6.
98. Wang H, ..., **Fereshtehnejad SM**, ..., Murray CJ. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014 Sep 13;384(9947):957-79. doi: 10.1016/S0140-6736(14)60497-9.
 99. **Fereshtehnejad SM**, Ghazi L, Sadeghi M, Khaefpanah D, Shahidi GA, Delbari A, Lökk J. Prevalence of malnutrition in patients with Parkinson's disease: a comparative study with healthy controls using Mini Nutritional Assessment (MNA) questionnaire. *J Parkinsons Dis*. 2014;4(3):473-81. doi: 10.3233/JPD-130323.
 100. **Fereshtehnejad SM**, Lökk J. Orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. *Parkinsons Dis*. 2014;2014:475854. doi: 10.1155/2014/475854.
 101. Eriksson H, **Fereshtehnejad SM**, Falahati F, Farahmand B, Religa D, Eriksdotter M. Differences in routine clinical practice between early and late onset Alzheimer's disease: data from the Swedish Dementia Registry (SveDem). *J Alzheimers Dis*. 2014;41(2):411-9. doi: 10.3233/JAD-132273.
 102. **Fereshtehnejad SM**, Ghazi L, Shafieesabet M, Shahidi GA, Delbari A, Lökk J. Motor, psychiatric and fatigue features associated with nutritional status and its effects on quality of life in Parkinson's disease patients. *PLoS One*. 2014 Mar 7;9(3):e91153. doi: 10.1371/journal.pone.0091153.
 103. **Fereshtehnejad SM**, Johnell K, Eriksdotter M. Anti-dementia drugs and co-medication among patients with Alzheimer's disease: investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem). *Drugs Aging*. 2014 Mar;31(3):215-24. doi: 10.1007/s40266-014-0154-8.
 104. Javadmoosavi SA, Shahabi Shahmiri S, Mostafapour E, Purfakharan M, Zamanzadeh M, **Fereshtehnejad SM**, Raji H. Comparison of the serum concentration of zinc in patients with bronchiectasis and control group. *Iran Red Crescent Med J*. 2013 Jul;15(7):587-9. doi: 10.5812/ircmj.7735.
 105. **Fereshtehnejad SM**, Hadizadeh H, Farhadi F, Shahidi GA, Delbari A, Lökk J. Reliability and validity of the persian version of the fatigue severity scale in idiopathic Parkinson's disease patients. *Parkinsons Dis*. 2013;2013:935429. doi: 10.1155/2013/935429.
 106. Borghei-Razavi H, **Fereshtehnejad SM**, Khanbabazadeh S, Daneshi A, Schick U. "Münster correlation" in temporal bone: surgical relevance of an anatomical study. *Anat Sci Int*. 2014 Mar;89(2):112-7. doi: 10.1007/s12565-013-0206-x.
 107. Mehrpour M, Hajsadeghi S, **Fereshtehnejad SM**, Mehrpour M, Bassir P. Serum levels of cardiac troponin I in patients with status epilepticus and healthy cardiovascular system. *Arch Med Res*. 2013 Aug;44(6):449-53. doi: 10.1016/j.arcmed.2013.09.005.
 108. Shahbeigi S, Pakdaman H, **Fereshtehnejad SM**, Nikravesh E, Mirabi N, Jalilzadeh G. Vitamin D3 concentration correlates with the severity of multiple sclerosis. *Int J Prev Med*. 2013 May;4(5):585-91.

109. Rezvani M, Zamani B, **Fereshtehnejad SM**. Factors affecting the efficacy of pramipexole in patients with restless legs syndrome. *Acta Med Iran*. 2013 Jul 13;51(6):377-85.
110. Forogh B, Yazdi-Bahri SM, Ahadi T, **Fereshtehnejad SM**, Raissi GR. Comparison of two protocols of transcranial magnetic stimulation for treatment of chronic tinnitus: a randomized controlled clinical trial of burst repetitive versus high-frequency repetitive Transcranial Magnetic Stimulation. *Neurol Sci*. 2014 Feb;35(2):227-32. doi: 10.1007/s10072-013-1487-5.
111. **Fereshtehnejad SM**, Religa D, Westman E, Aarsland D, Lökk J, Eriksdotter M. Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). *Neuropsychiatr Dis Treat*. 2013;9:927-35. doi: 10.2147/NDT.S45840.
112. Shabani Zanjani M, Nasirzadeh R, **Fereshtehnejad SM**, Yoonesi Asl L, Alemzadeh SA, Askari S. Fetal cerebral hemodynamic in gestational diabetic versus normal pregnancies: a Doppler velocimetry of middle cerebral and umbilical arteries. *Acta Neurol Belg*. 2014 Mar;114(1):15-23. doi: 10.1007/s13760-013-0221-7.
113. Madani SP, Fateh HR, Forogh B, **Fereshtehnejad SM**, Ahadi T, Ghaboussi P, Bouhassira D, Raissi GR. Validity and reliability of the persian (Farsi) version of the DN4 (Douleur Neuropathique 4 Questions) questionnaire for differential diagnosis of neuropathic from non-neuropathic pains. *Pain Pract*. 2014 Jun;14(5):427-36. doi: 10.1111/papr.12088.
114. Moosavi SA, Raji H, Tasorian B, Mostafapour E, Shahabi S, Purfakharan M, **Fereshtehnejad SM**. Effect of Zafirlukast on improving lung function in patients with chronic obstructive pulmonary diseases. *Med J Islam Repub Iran*. 2013 May;27(2):57-61.
115. Kazemi H, Ghassemi S, **Fereshtehnejad SM**, Amini A, Kolivand PH, Doroudi T. Anxiety and depression in patients with amputated limbs suffering from phantom pain: a comparative study with non-phantom chronic pain. *Int J Prev Med*. 2013 Feb;4(2):218-25.
116. Mehrpour M, Khuzan M, Najimi N, Motamed MR, **Fereshtehnejad SM**. Serum uric acid level in acute stroke patients. *Med J Islam Repub Iran*. 2012 May;26(2):66-72.
117. Bejeh Mir KP, Mohagheghi P, Bejeh Mir AP, **Fereshtehnejad SM**. New Predictors for Advanced Retinopathy of Prematurity among Neonates in Tehran/Iran. *Iran J Pediatr*. 2012 Sep;22(3):375-84.
118. Hajsadeghi S, **Fereshtehnejad SM**, Ojaghi M, Bassiri HA, Keramati MR, Chitsazan M, Gholami S. Doppler echocardiographic indices in aortic coarctation: a comparison of profiles before and after stenting. *Cardiovasc J Afr*. 2012 Oct;23(9):483-90. doi: 10.5830/CVJA-2012-044.
119. Borji R, **Fereshtehnejad SM**, Taba Taba Vakili S, Daryani NE, Ajdarkosh H. Association between irritable bowel syndrome and restless legs syndrome: a comparative study with control group. *J Neurogastroenterol Motil*. 2012 Oct;18(4):426-33. doi: 10.5056/jnm.2012.18.4.426.
120. Hajsadeghi S, **Fereshtehnejad SM**, Gholami S, Chitsazan M, Keramati MR. Pulsatility index in aortic coarctation: a possible way to evaluate factors affecting stenting outcome. *J Tehran Heart Cent*. 2012 Winter;7(1):19-24.

121. Zamani F, Bagheri Z, Bayat M, **Fereshtehnejad SM**, Basi A, Najmabadi H, Ajdarkosh H. Iranian hereditary hemochromatosis patients: baseline characteristics, laboratory data and gene mutations. *Med Sci Monit.* 2012 Oct;18(10):CR622-9.
122. Shahbeigi S, **Fereshtehnejad SM**, Mohammadi N, Golmakani MM, Tadayyon S, Jalilzadeh G, Pakdaman H. Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010. *Neurol Sci.* 2013 Jul;34(7):1157-66. doi: 10.1007/s10072-012-1200-0.
123. Fereydoonian NA, Bakhti S, **Fereshtehnejad SM**, Tabibkhouei AR. Intramedullary thoracic spine epidermoid cyst with myelopathic presentations: a report of a rare case. *Clin Neurol Neurosurg.* 2013 Jun;115(6):841-3. doi: 10.1016/j.clineuro.2012.08.002.
124. Nazerani S, Keramati MR, Vahedian J, **Fereshtehnejad SM**. Soft tissue distraction using pentagonal frame for long-standing traumatic flexion deformity of interphalangeal joints. *Chin J Traumatol.* 2012;15(4):206-11.
125. **Fereshtehnejad SM**, Delbari A, Lökk J. Methods for assessing mortality in Parkinson's disease surveys. *Mov Disord.* 2012 Jun;27(7):926 doi: 10.1002/mds.25021.
126. Ghajarzadeh M, Hassanpour K, **Fereshtehnejad SM**, Jamali A, Nedjat S, Aramesh K. Attitude towards plagiarism among Iranian medical students. *J Med Ethics.* 2013 Apr;39(4):249. doi: 10.1136/medethics-2012-100560.
127. **Fereshtehnejad SM**, Poorsattar Bejeh Mir K, Poorsattar Bejeh Mir A, Mohagheghi P. Evaluation of the possible antioxidative role of bilirubin protecting from free radical related illnesses in neonates. *Acta Med Iran.* 2012;50(3):153-63.
128. Anbardan SJ, Daryani NE, **Fereshtehnejad SM**, Taba Taba Vakili S, Keramati MR, Ajdarkosh H. Gender Role in Irritable Bowel Syndrome: A Comparison of Irritable Bowel Syndrome Module (ROME III) Between Male and Female Patients. *J Neurogastroenterol Motil.* 2012 Jan;18(1):70-7. doi: 10.5056/jnm.2012.18.1.70.
129. Hoseini R, Otukesh H, **Fereshtehnejad SM**, Tahoori A, Hooman N, Rahimzadeh N, Sadr S. Prevalence and outcome of focal segmental glomerulosclerosis in Iranian children with nephrotic syndrome. *Iran J Kidney Dis.* 2012 Jan;6(1):18-24.
130. Mousavi SA, Shahabi S, Mostafapour E, Purfakharan M, **Fereshtehnejad SM**, Amini J, Khojandi M, Raji H. Comparison of the Serum Electrolyte Levels among Patients Died and Survived in the Intensive Care Unit. *Tanaffos.* 2012;11(4):36-42.
131. Harandi AA, Shahbeigi S, Pakdaman H, **Fereshtehnejad SM**, Nikravesh E, Jalilzadeh R. Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. *Iran J Neurol.* 2012;11(2):54-8.
132. Khosravi S, Alavian SM, Zare A, Daryani NE, **Fereshtehnejad SM**, Daryani NE, Keramati MR, Abdollahzade S, Taba Taba Vakili S. Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings. *Hepat Mon.* 2011 Jun;11(6):452-8.
133. Otukesh H, Hoseini R, Behzadi AH, **Fereshtehnejad SM**, Mehrazma M, Parvin M, Mojtahedzadeh M, Razizadeh N, Pourfakharan M. Renal amyloidosis in a child with neutropenia. *Saudi J Kidney Dis Transpl.* 2011 Sep;22(5):1019-21.

134. Otukesh H, Hoseini R, Rahimzadeh N, **Fereshtehnejad SM**, Simfroosh N, Basiri A, Sharifian M, Hashemi GH, Falahzadeh H, Derakhshan A, Fazel M, Reiesee D, Sayedzadeh A, Vazirian S, Nikibakhsh AA, Moghadam AG, Mohamadzadeh H, Naderi A, Isfahani T, Larijani F, Shorkhi H, Pasha AA, Shahbazian H, Valavi E, Mortazavi F, Gheisari A. Outcome of renal transplantation in children: a multi-center national report from Iran. *Pediatr Transplant*. 2011 Aug;15(5):533-8. doi: 10.1111/j.1399-3046.2011.01507.x.
135. Nobakht H, Zamani F, Ajdarkosh H, Mohamadzadeh Z, **Fereshtehnejad SM**, Nassaji M. Adult-onset familial mediterranean Fever in northwestern iran; clinical feature and treatment outcome. *Middle East J Dig Dis*. 2011 Mar;3(1):50-5.
136. Zamani B, Mehrabani M, **Fereshtehnejad SM**, Rohani M. Evaluation of cerebral vasomotor reactivity in Parkinson's disease: is there any association with orthostatic hypotension? *Clin Neurol Neurosurg*. 2011 Jun;113(5):368-72. doi: 10.1016/j.clineuro.2010.12.014.
137. Madani A, Isfahani ST, Rahimzadeh N, **Fereshtehnejad SM**, Hoseini R, Moghtaderi M, Mohseni P, Ataiee N. Effect of levamisole in steroid-dependent nephrotic syndrome. *Iran J Kidney Dis*. 2010 Oct;4(4):292-6.
138. Daryani NE, Daryani NE, Alavian SM, Zare A, **Fereshtehnejad SM**, Keramati MR, Pashaei MR, Habibollahi P. Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. *World J Gastroenterol*. 2010 Sep 7;16(33):4169-75.
139. Mohammadinia AR, Bakhtavar K, Ebrahimi-Daryani N, Habibollahi P, Keramati MR, **Fereshtehnejad SM**, Abdollahzade S. Correlation of hepatic vein Doppler waveform and hepatic artery resistance index with the severity of nonalcoholic fatty liver disease. *J Clin Ultrasound*. 2010 Sep;38(7):346-52. doi: 10.1002/jcu.20696.
140. Motazedian S, Babakhani L, **Fereshtehnejad SM**, Mojtahedi K. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. *Indian J Med Res*. 2010 May;131:670-4.
141. Arshi S, Zarrinfard R, Poorsattar A, **Fereshtehnejad SM**, Javahertarash N. Prick test: a survey and comparison between Iranian allergic children and adults. *Allergol Immunopathol (Madr)*. 2010 Sep-Oct;38(5):287-90. doi: 10.1016/j.aller.2009.12.004.
142. Shahmiri SS, Adeli SH, Mousavi SA, Mostafapour E, **Fereshtehnejad SM**, Namegh B, Ziaeenejad MT. Evaluation of the simvastatin effects in the treatment of pulmonary hypertension (PH). *Lijec Vjesn*. 2009 Nov;131 Suppl 6:12-5.
143. Mostafapour E, Mousavi SA, Shahmiri SS, **Fereshtehnejad SM**. Effects of combination of fluticasone propionate and salmeterol xinafoate on lung function improvement in patients with bronchiectasis. *Lijec Vjesn*. 2009 Nov;131 Suppl 6:8-11.
144. Otukesh H, Otukesh S, Mojtahedzadeh M, Hoseini R, **Fereshtehnejad SM**, Riahi Fard A, Sadigh N, Heshmatzade Behzadi A, Javadi R, Hooman N, Mehrazma M. Management and outcome of steroid-resistant nephrotic syndrome in children. *Iran J Kidney Dis*. 2009 Oct;3(4):210-7.
145. Shidfar F, Homayounfar R, **Fereshtehnejad SM**, Kalani A. Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial. *Arch Med Res*. 2009 Jul;40(5):380-6. doi: 10.1016/j.arcmed.2009.06.004.

146. Otukesh H, Sharifiaghdas F, Hoseini R, **Fereshtehnejad SM**, Rabiee N, Kiaiee MF, Javadi R, Mojtahedzadeh M, Simfroosh N, Basiri A, Hooman N, Nasiri J, Delshad S, Farhood P. Long-term upper and lower urinary tract functions in children with posterior urethral valves. *J Pediatr Urol*. 2010 Apr;6(2):143-7. doi: 10.1016/j.jpuro.2009.06.016.
147. Otukesh H, Hosein R, **Fereshtehnejad SM**, Riahifard A, Basiri A, Simforoosh N, Chalian M, Jazayeri S, Chalian H, Safarzadeh AE, Sharifian M, Hoseini S. Short-term and long-term effects of slow graft function on graft survival in pediatric live donor renal transplantation. *Pediatr Transplant*. 2010 Mar;14(2):196-202. doi: 10.1111/j.1399-3046.2009.01191.x.
148. Hajsadeghi S, **Fereshtehnejad SM**, Pourshirmohammadi-Sabzevari M, Khamseh ME, Noohi F. Renal artery stenosis in hypertensive patients with or without type 2 diabetes: a comparative magnetic resonance angiography study. *Arch Iran Med*. 2009 May;12(3):250-5.
149. Otukesh H, Ghazanfari B, **Fereshtehnejad SM**, Bakhshayesh M, Hashemi M, Hoseini R, Chalian M, Salami A, Mehdipor L, Rahiminia A. NPHS2 mutations in children with steroid-resistant nephrotic syndrome. *Iran J Kidney Dis*. 2009 Apr;3(2):99-102.
150. Memari F, Tabatabaee RM, Borghei Razavi H, **Fereshtehnejad SM**, Daneshi A. Transpetrosal approach: an anatomical study of temporal bone. *Eur Arch Otorhinolaryngol*. 2009 Sep;266(9):1373-80. doi: 10.1007/s00405-009-0928-5.
151. Hajsadeghi S, Afsharian S, **Fereshtehnejad SM**, Keramati MR, Mollahoseini R. Serum levels of cardiac troponin I in patients with uncomplicated epileptic seizure. *Arch Med Res*. 2009 Jan;40(1):24-8. doi: 10.1016/j.arcmed.2008.10.002.
152. Otukesh H, Hoseini R, Golnari P, **Fereshtehnejad SM**, Zamanfar D, Hooman N, Tabarroki A. Short-term and long-term outcome of hemolytic uremic syndrome in Iranian children. *J Nephrol*. 2008 Sep-Oct;21(5):694-703.
153. Otukesh H, **Fereshtehnejad SM**, Hoseini R, Hekmat S, Chalian H, Chalian M, Bedayat A, Salman Yazdi R, Sabaghi S, Mahdavi S. Urine macrophage migration inhibitory factor (MIF) in children with urinary tract infection: a possible predictor of acute pyelonephritis. *Pediatr Nephrol*. 2009 Jan;24(1):105-11. doi: 10.1007/s00467-008-0969-9.
154. Otukesh H, Hoseini R, **Fereshtehnejad SM**, Behzadi AH, Chalian M, Jazayeri M, Chalian H, Javadi R. Outcome of living donor renal allograft survival in children with focal segmental glomerulosclerosis. *Pediatr Transplant*. 2009 Feb;13(1):39-43. doi: 10.1111/j.1399-3046.2008.00994.x.
155. Valavi E, Otukesh H, **Fereshtehnejad SM**, Sharifian M. Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy. *Pediatr Transplant*. 2008 Nov;12(7):748-54. doi: 10.1111/j.1399-3046.2008.00981.x.
156. Etemadian M, Haghighi R, Madineay A, Tizeno A, **Fereshtehnejad SM**. Delayed versus same-day percutaneous nephrolithotomy in patients with aspirated cloudy urine. *Urol J*. 2008 Winter;5(1):28-33.
157. Yahyavi S, Parsa FM, **Fereshtehnejad SM**, Najimi N. Objective measurement of nasal airway dimensions and resistance using acoustic rhinometry and rhinomanometry in habitual snorers compared with non-snorers. *Eur Arch Otorhinolaryngol*. 2008 Dec;265(12):1483-7. doi: 10.1007/s00405-008-0673-1.

158. Otukesh H, Basiri A, Simfroosh N, Hoseini R, **Fereshtehnejad SM**, Chalian M. Kidney transplantation in children with posterior urethral valves. *Pediatr Transplant*. 2008 Aug;12(5):516-9. doi: 10.1111/j.1399-3046.2007.00846.x.
159. Razzaghy-Azar M, Moghimi A, Sadigh N, Montazer M, Golnari P, Zahedi-Shoolami L, Van Buuren S, Mohammad-Sadeghi H, Zangeneh-Kazemi A, **Fereshtehnejad SM**. Age of puberty in Iranian girls living in Tehran. *Ann Hum Biol*. 2006 Sep-Dec;33(5-6):628-33.
160. Motamed MR, Najimi N, **Fereshtehnejad SM**. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. *Clin Neurol Neurosurg*. 2007 May;109(4):344-9.
161. Razzaghy Azar M, Moghimi A, Montazer M, Sadeghi HM, Golnari P, Sadigh N, Ossivand S, **Fereshtehnejad SM**, Shoolami LZ, Pour NE. Cross-sectional reference values for height, weight and body mass index of school children living in Tehran, Iran. *Ann Hum Biol*. 2006 Jul-Aug;33(4):471-9.
162. Otukesh H, Basiri A, Simfroosh N, Hoseini R, Sharifian M, Sadigh N, Golnari P, Rezai M, **Fereshtehnejad M**. Outcome of pediatric renal transplantation in Labfi Nejad Hospital, Tehran, Iran. *Pediatr Nephrol*. 2006 Oct;21(10):1459-63.
163. Otukesh H, Sharifian M, Simfroosh N, Basiri A, Hoseini R, Sedigh N, Golnari P, Rezai M, **Fereshtehnejad M**. Outcome of renal transplantation in children with low urinary tract abnormality. *Transplant Proc*. 2005 Sep;37(7):3071-4.
164. Otukesh H, Sharifian M, Basiri A, Simfroosh N, Hoseini R, Sedigh N, Golnari P, Rezai M, **Fereshtehnejad M**. Mycophenolate mofetil in pediatric renal transplantation. *Transplant Proc*. 2005 Sep;37(7):3012-5.

7.3 PUBLISHED BOOKS

1. Chehrei A, Haghdoost AA, **Fereshtehnejad SM**, Bayat A, eds. Statistical Methods in Medical Science Researches Using SPSS Software. [ISBN: 978-600-5217-22-3] First Edition, Pazhvak e Elm e Arya Publication, Tehran, Iran (2010) [Persian]
2. Chehrei A, Shahgholi N, Saberi M, Sadigh N, **Fereshtehnejad SM**, Mohammad Sadeghi H, Moradi M, Moghimi A, Montazer M, Hashemnejad M, eds. Sampling and Sample Size Calculation in Medical Research. [ISBN: 964-93428-9-3] Second Edition, Pazhvak e Elm e Arya Publication, Tehran, Iran (2007) [Persian]
3. Chehrei A, Bayat A, Moghimi A, **Fereshtehnejad SM**, Kahbazi M, eds. Basic Principles of Medical Scientific Notation. [ISBN: 964-93428-0-X] First Edition, Pazhvak e Elm e Arya Publication, Tehran, Iran (2007) [Persian]
4. Chehrei A, Kahbazi M, Zarganj Fard A, Dorreh F, Bayat A, **Fereshtehnejad SM**, Golnari P, eds. The Principles of Designing Randomized Controlled Trials. [ISBN: 964-7621-10-8] First Edition, Arak University of Medical Sciences Publication, Arak, Iran (2006) [Persian]

8. CONGRESS PRESENTATIONS

8.1 ORAL PRESENTATION

1. Network atrophy in early stage predicts longitudinal rate of progression in Parkinson's disease. In: 23rd Annual Meeting of the Organization for Human Brain Mapping (OHBM),

Vancouver, Canada (25-29 June 2017)

2. Comorbidity and co-medication profiles in patients with Alzheimer's disease: a linkage study of three Swedish registries. In: *23th Nordic Congress of Gerontology (NKG), Tampere, Finland (19-22 June 2016)*
3. Heterogeneous determinants of quality of life in different phenotypes of Parkinson's disease. In: *XXII World Congress of Neurology (WCN), Santiago, Chile (31 October-5 November 2015)*
4. Dementia diagnosis, treatment and care in specialist clinics in two Scandinavian countries: A data comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry. In: *Alzheimer's Association International Conference (AAIC), Copenhagen, Denmark (12-17 July 2014)*
5. The importance of Clinical Practice Guidelines (CPG). In: *1st National Seminar on Referral System of Acute Stroke Patients to the Stroke Units, Tehran, Iran (13 May 2011)*
6. Estimation of life expectancy and its association with social determinants of health (SDH) in urban population of different districts of Tehran in 2008. In: *1st National Congress on Urban Health, Tehran, Iran (24-25 April 2010)*
7. Evaluation of the association between history of radiation and multiple sclerosis: A case control study. In: *6th International Congress on Multiple Sclerosis, Tabriz, Iran (15-16 October 2009)*
8. Evaluation of the effect of viral hepatitis B and C on graft survival in renal transplant recipients. In: *2nd Tehran Hepatitis Congress, Tehran, Iran (7-9 October 2009)*
9. Evaluation of the serum cardiac troponin I (cTnI) level in non-cardiac uncomplicated epileptic patients. In: *16th Congress of the Iranian Heart Association, Tehran, Iran (18-21 November 2008)*
10. Dual antiplatelet therapy with clopidogrel and aspirin for stroke prevention following transient ischemic attack (TIA) or mild-to-moderate ischemic stroke. In: *9th National Medical Students' Research Congress, Mashhad, Iran (25-27 May 2008)*
11. The effect of halo traction between anterior and posterior spinal fusion on the correction of scoliosis. In: *8th National Medical Students' Research Congress, Shiraz, Iran (23-25 May 2007)*
12. The evaluation of urine macrophage migration inhibitory factor (MIF) in children with urinary tract infection: A possible predictor of acute pyelonephritis. In: *International Medical Students Research Congress, Istanbul, Turkey (11-13 May 2007)*
13. Objective measurement of nasal airway dimensions and resistance using acoustic rhinometry and rhinomanometry in habitual snorers compared with non-snorers. In: *1st Medical Students' Research Congress of the city of Tehran, Tehran, Iran (27-28 December 2006)*
14. Correlation between urine macrophage migration inhibitory factor (MIF)/creatinine ratio and time after kidney transplantation: A possible predictor of pediatric chronic allograft nephropathy. In: *1st Medical Students' Research Congress of the city of Tehran, Tehran, Iran (27-28 December 2006)*
15. A comparative study of the effects of herbal therapy with carmint versus those of

- dimethicone on flatulence. In: *7th National Medical Students' Research Congress, Tehran, Iran* (30 May-1 June 2006)
16. Determination of the relationship between reflux esophagitis and hiatal hernia. In: *1st Health Praxis Asia, Kuala Lumpur, Malaysia* (16-18 December 2005)
 17. The comparison of sex hormones and interferon's impacts on the number of relapses and the progression of disability in relapsing-remitting multiple sclerosis (RRMS). In: *6th National Medical Students' Research Congress, Sari, Iran* (26-28 April 2005)
 18. Evaluation of the effects of mycophenolate mofetil on the survival of pediatric renal transplants. In: *5th National Medical Students' Research Congress, Mashhad, Iran* (13-15 October 2004)

8.2 POSTER PRESENTATION

1. Network atrophy in early stage predicts longitudinal rate of progression in Parkinson's disease. In: *23rd Annual Meeting of the Organization for Human Brain Mapping (OHBM), Vancouver, Canada* (25-29 June 2017)
2. Validation of the MDS Research Criteria for Prodromal Parkinson's Disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. In: *21st International Congress of Parkinson's Disease and Movement Disorders (MDS), Vancouver, Canada* (4-8 June 2017)
3. Clinical Criteria for Subtyping Parkinson's Disease: Differences in imaging and CSF biomarkers and longitudinal progression. In: *21st International Congress of Parkinson's Disease and Movement Disorders (MDS), Vancouver, Canada* (4-8 June 2017)
4. Hyperechogenicity of substantia nigra for differentiation of idiopathic Parkinson's disease from other movement disorders: A systematic review and meta-analysis of transcranial ultrasonography (TCS) studies. In: *4th World Parkinson Congress (WPC), Portland, Oregon, USA* (20-23 September 2016)
5. Cardiovascular and cerebrovascular disorders are associated with a higher prevalence of parkinsonism: Data from a neuroepidemiologic community-based survey. In: *20th International Congress of Parkinson's Disease and Movement Disorders (MDS), Berlin, Germany* (19-23 June 2016)
6. Clinical subtypes of Parkinson's disease and disease progression: data-driven comparison of new phenotypes with other cluster solutions. In: *19th International Congress of Parkinson's Disease and Movement Disorders (MDS), San Diego, CA, USA* (14-18 June 2015)
7. Restless legs syndrome (RLS) in patients with Parkinson's disease: a comparative study on prevalence and clinical characteristics. In: *10th International Congress on Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders, Nice, France* (4-7 December 2014)
8. Diagnosis and treatment in early-onset Alzheimer's disease patients in Sweden and Denmark: Cross-sectional analyses of data from two dementia registries from specialist clinics. In: *Alzheimer's Association International Conference (AAIC), Copenhagen, Denmark* (12-17 July 2014)
9. Devising a new screening instrument for Parkinsonism: comparison of discriminative ability of different questionnaires. In: *18th International Congress of Parkinson's Disease and Movement Disorders (MDS), Stockholm, Sweden* (8-12 June 2014)

10. Screening of Parkinsonism in Tehran urban area, Iran: a community-based door-to-door prevalence-study in the year 2012. In: *18th International Congress of Parkinson's Disease and Movement Disorders (MDS), Stockholm, Sweden (8-12 June 2014)*
11. Evaluation of the factors affecting psychosocial functioning of patients with Parkinson's disease. In: *Joint Congress of European Neurology, Istanbul, Turkey (31 May-3 June 2014)*
12. Anti-dementia drugs and co-medication amongst patients with Alzheimer's disease: Investigating real-world drug use in clinical practice using the Swedish Dementia Registry (SveDem). In: *22nd Nordic Congress of Gerontology (NKG), Gothenburg, Sweden (25-28 May 2014)*
13. Nutritional status correlates with non-motor and motor symptoms of Parkinson's disease: A cross-sectional analysis in 143 patients. In: *3rd World Parkinson Congress (WPC), Montreal, Canada (1-4 October 2013)*
14. Comparison of the psychological symptoms and disease-specific quality of life (QoL) between early- versus late-onset Parkinson's disease patients. In: *3rd World Parkinson Congress (WPC), Montreal, Canada (1-4 October 2013)*
15. Kinematic and kinetic continuous measurement of hand tremor to discriminate Parkinson's disease: a pilot single-case study. In: *3rd World Parkinson Congress (WPC), Montreal, Canada (1-4 October 2013)*
16. Effect of training workshop on quality of students' peer reviewing of research abstracts: a one-arm self-control educational intervention. In: *7th International Congress on Peer Review and Biomedical Publication, Chicago, Illinois, USA (8-10 September 2013)*
17. Disease severity and diagnostic approach in dementia with Lewy bodies and Parkinson's disease with dementia: data from SveDem registry. In: *11th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD), Florence, Italy (6-10 March 2013)*
18. Leading integrative healthcare: The case of treating Parkinson's disease. In: *6th NOVO Symposium, Stockholm, Sweden (15-16 November 2012)*
19. Foetal middle cerebral and arteries of umbilical blood flow velocity in normal and gestational diabetic pregnancies. In: *16th Congress of the European Federation of Neurological Societies (EFNS 2012) Stockholm, Sweden (8-11 September 2012)*
20. Association between irritable bowel syndrome and restless legs syndrome: a comparative study with control group. In: *16th Congress of the European Federation of Neurological Societies (EFNS 2012) Stockholm, Sweden (8-11 September 2012)*
21. Comparison of the long-term effects of hypobaric condition of pilots versus hyperbaric condition of divers on blood flow velocity of middle cerebral, basilar and carotid arteries using transcranial Doppler and Duplex ultrasonography. In: *1st International Congress of Neurosonology & Cerebral Hemodynamic of Iran, Tehran, Iran (3-4 March 2011)*
22. Comparison of the effect of interferon (IFN) beta-1b (Betaferon) and beta-1a (Rebif) on brain MRI lesions in patients with remitting-relapsing multiple sclerosis (RRMS). In: *6th International Congress on Multiple Sclerosis, Tabriz, Iran (15-16 October 2009)*
23. Dual antiplatelet therapy with clopidogrel and aspirin for stroke prevention following transient ischemic attack (TIA) or mild-to-moderate ischemic stroke. In: *16th Iranian Congress of Neurology, Tehran, Iran (19-22 May 2009)*

24. The effect of interferon β -1b on the number of plaques and different sites of brain MRI lesions in relapsing-remitting multiple sclerosis (RRMS). In: *5th International Congress on Multiple Sclerosis, Tehran, Iran* (13-14 November 2008)
25. Comparison of short-term and long-term outcomes of spinal fusion with and without posterior instrumentation in congenital scoliosis. In: *International Medical Students Research Congress, Istanbul, Turkey* (11-13 May 2007)
26. Effects of cadmium on cellular and subcellular structures of cerebellar Purkinje cells in four-day postnatal developing rat. In: *13th International Student Congress of Medical Sciences, Groningen, The Netherlands* (14-17 June 2006)
27. Effects of cadmium on cellular and subcellular structures of cerebellar Purkinje cells in four-day postnatal developing rat. In: *7th National Medical Students' Research Congress, Tehran, Iran* (30 May-1 June 2006)
28. Determination of the serum and blood indexes in end stage renal disease (ESRD) Patients in hemodialysis centers in Iran from 1978 to 2004. In: *4th Leiden international medical student congress, Leiden, The Netherlands* (7-9 April 2005)

9. PATENTS

Early diagnosis of acute pyelonephritis from acute cystitis using urine macrophage migration inhibitory factor (MIF)/Creatinine ratio in children with urinary tract infection (UTI)

Patent No.: **54936**

Declaration registration No.: **38708926**

Registration date: **26 November 2008**

Delivery and protection date: **13 November 2008**

10. AWARDS, HONOURS

10.1 ACADEMIC

1. First-Rank Graduate Student, Master of Public Health (MPH), Iran University of Medical Sciences, Overall GPA: 18.83/20 (2008-2009)
2. Exemplary University Student in Iran, Presidential Award (2007)
3. First-Rank Medical Student, 3rd semester, Iran University of Medical Sciences, Overall GPA: 17.88/20 (2002-2003)
4. Second-Rank Medical Student, 1st semester, Iran University of Medical Sciences, Overall GPA: 17.12/20 (2001-2002)

10.2 RESEARCH

1. Merit Abstract Award, '*23rd Annual Meeting of the Organization for Human Brain Mapping (OHBM)*', Vancouver, Canada (25-29 June 2017)
2. Exceptional Abstract, '*21st International Congress of Parkinson's Disease and Movement Disorders (MDS)*', Vancouver, Canada (4-8 June 2017)
3. Top Three Finalists, 'Parkinson's Progression Markers Initiative (PPMI) Data Challenge 2016', Michael J. Fox Foundation, USA (30 December 2016)
4. Most Bold and Beautiful Project Award, '*HealthHack Academy*', Stockholm, Sweden (13

September 2015)

5. Outstanding Reviewer Award, 'Elsevier Publisher' (24 October 2014)
6. Best Workshop Instructor (Publication Strategy), '11th National Seminar of Knowledge and Health', Shahroud University of Medical Sciences, Shahroud, Iran (19-20 December 2011)
7. Best Poster Presentation Award, '1st International Congress of Neurosonology and Cerebral Hemodynamic', Tehran, Iran (3-4 March 2011)
8. Best National Young Researcher Award, Section of Clinical Research (Internal Medicine), '15th National Razi Research Festival on Medical Sciences', Tehran, Iran (January 2010)
9. First-Rank Student Oral Presentation Award, '2nd Tehran Hepatitis Congress', Tehran, Iran (7-9 October 2009)
10. Best Poster Presentation Award, '16th International Congress of Neurology and Clinical Electrophysiology', Tehran, Iran (19-22 May 2009)
11. Best Student Researcher of 'Iran University of Medical Sciences' (2008)
12. Best Oral Presentations Award, 'Istanbul International Medical Student Congress', Istanbul, Turkey (10-13 May 2007)
13. Best Student Researcher of 'Iran University of Medical Sciences' (2007)
14. Third-Rank Oral Presentation Award, '1st Medical Students' Research Congress of the City of Tehran', Tehran, Iran (27-28 December 2006)
15. President of the Best Medical Student Research Committee, '11th National Razi Research Festival on Medical Sciences', Tehran, Iran (January 2006)
16. Best Presentation Diploma, awarded by the National Institute of Health (NIH) of Armenia, '3rd Young Medics' International Conference', Yerevan, Armenia (19-21 September 2005)
17. Second-Rank Oral Presentation Award, '5th National Medical Students' Research Congress', Mashhad, Iran (13-15 October 2004)

11. GRANTS, SCHOLARSHIPS

11.1 SCHOLARSHIP

1. Postdoctoral Fellowship, *Canada First Research Excellence Fund for the Healthy Brains for Healthy Lives (HBHL) initiative*, McGill University, Montreal, Canada - \$35,000 (2017)
2. Postdoctoral Fellowship, *Richard and Edith Strauss Scholarship*, Faculty of Medicine, McGill University, Montreal, Canada - \$8,750 (2016)
3. Postdoctoral Fellowship, *Preston Robb Scholarship*, Montreal Neurological Institute (MNI), McGill University, Montreal, Canada - \$40,000 (2016)
4. Student Fellowship, *McGill University Health Center (MUHC)*, Montreal, Canada - \$5,950 (2016)
5. Summer Student Scholarship, *Parkinson Disease Foundation (PDF)*, USA - \$4,000 (2014)
6. Summer School Scholarship, *Doctoral Program in Neuroscience/StratNeuro*, Stockholm, Sweden - \$1,920 (12,500 SEK) (2013)
7. Summer School Scholarship, *Modern Methods in Biostatistics and Epidemiology*, Treviso, Italy - \$1,700 (€1,150) (2013)

11.2 RESEARCH GRANT

1. Main Applicant, *Swedish Alzheimer's Foundation (Alzheimerfonden)*, Stockholm, Sweden - \$30,700 (200,000 SEK) (2015)
2. Co-Applicant, *Swedish Parkinson Foundation (Parkinsonfonden)*, Stockholm, Sweden - \$11,500 (75,000 SEK) (2014)
3. Co-Applicant, *Swedish Parkinson Foundation (Parkinsonfonden)*, Stockholm, Sweden - \$15,400 (100,000 SEK) (2012)
4. Main Applicant, *SEB Bank Research Grant*, Stockholm, Sweden - \$3,000 (20,000 SEK) (2012)

12. MANAGEMENT, LEADERSHIP

1. Scientific Editor, '*Medical Journal of the Islamic Republic of Iran*' (February 2011- February 2014)
2. Head of the Reviewers Committee, '*12th National Iranian Medical Students' Research Congress*', Esfahan, Iran (February 2011- September 2011)
3. Director, '*Firoozgar Clinical Research Development Center (FCRDC)*', Tehran, Iran (April 2010- January 2012)
4. Head of the Reviewers Committee, '*11th National Iranian Medical Students' Research Congress*', Bandar Abbas, Iran (February 2010- April 2010)
5. Associate Editor, '*Iranian Journal of Neurology*' (September 2009- September 2010)
6. Vice-secretor of the Proposal Committee, '*Gastrointestinal and Liver Disease Research Center (GILDRC)*', Iran University of Medical Sciences (December 2009- January 2012)
7. President, '*10th National Iranian Medical Students' Research Congress and the 1st Students International Conference on Biomedical and Interdisciplinary Research (SICOBAIR 2009)*', Tehran, Iran (September 2008- June 2009)
8. Research Secretary, '*Journal of Brain in Close-up*' (November 2007- September 2010)
9. Executive Manager, '*Iranian Journal of Neurology*' (August 2007-July 2009)
10. President, '*Medical Student Research Committee (MSRC)*', Faculty of Medicine, Iran University of Medical Sciences (2004-2005)
11. President, '*Medical Student Research Committee (MSRC)*', Division of Basic Sciences, Iran University of Medical Sciences (2002-2003)

13. MEMBERSHIPS

1. Editorial Board of the '*Iranian Journal of Aging*' (October 2016-Present)
2. Research Committee of the '*Iranian Aging Center*' (March 2015-Present)
3. '*International Movement Disorders Society (MDS)*' (December 2014-Present)
4. Expert Panel of the '*Global Burden of Disease (GBD) Study*' at the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA (September 2013-Present)
5. International Committee of '*Medicinska Föreningen*' at Karolinska Institutet, Stockholm, Sweden (November 2012-October 2013)
6. '*Parkinson's Disease Summer School (PDSS)*' Trainers (October 2012-Present)
7. Editorial Board of '*Journal of Sabzevar University of Medical Sciences*' (March 2012-Present)

8. Student Editorial Board of '*Thrita Journal of Medical Sciences*' (September 2011-Present)
9. Editorial board of '*World Journal of Nephrology*' (May 2011-Present)
10. Research Committee of '*Department of Neurology of Tehran University of Medical Sciences*' (April 2011-January 2012)
11. Research Committee of '*Department of Internal Medicine of Tehran University of Medical Sciences*' (January 2011- January 2012)
12. Research Committee of '*Firoozgar Clinical Research Development Center (FCRDC)*' (October 2010- January 2012)
13. Executive Board of the '*2nd Tehran Hepatitis Congress*' (7-9 October 2009)
14. Iranian Medical Council with the *M.C. No. of 123328* (September 2009-Present)
15. Management Consul of the '*Medical Student Research Committees of the Universities in Tehran Network*' (September 2009- January 2012)
16. Permanent Secretariat of the '*International and National Medical Student Research Congresses*' of Iran (September 2009- January 2012)
17. Editorial Board of the '*Journal of Brain in Close-up*' (November 2007- January 2012)
18. '*Gastrointestinal & Liver Disease Research Center (GILDRC)*' of Iran University of Medical Sciences (July 2007- January 2012)
19. '*Health System Research (HSR)*' committee of Iran University of Medical Sciences (December 2006-April 2009)
20. '*Medical Student Research Committee (MSRC)*' of Iran University of Medical Sciences (2001-2009)

14. TRAININGS

14.1 SUMMER SCHOOLS

1. Summer School on Modern Methods in Biostatistics and Epidemiology, Treviso, Italy (9-22 June 2013), Course topics:
 - Analysis of Prospective Studies using Stata
 - Multiple Imputation of Missing Data with Stata
 - Clinical Trials
 - Survival Analysis
 - Applied Longitudinal Analysis
 - Causal Inference
2. The 4th Parkinson's Disease Summer School for Healthcare Students, Warsaw, Poland (23 July-1 August 2012)

14.2 WORKSHOPS

1. fMRI: Basic and Advanced Methods (Montreal, Canada) (23-25 August 2016)
2. Project Management-I (Montreal, Canada) (10-11 February 2016)
3. Movement Disorders Phenomenology (EFNS/ENS Congress, Istanbul, Turkey) (31 May-3 June 2014)
4. Embryonic Stem Cell Culture (28-30 November 2010)
5. Good Clinical Practices (GCP) (3 November 2011)
6. Knowledge Translation (26 and 27 October 2011)

7. Systematic Reviews & Meta-Analysis (August 2011)
8. Application of Fuzzy Logic in Clinical Decision Making (14 March 2011)
9. Real Time PCR (12 and 13 December 2010)
10. Scientific Writing Ethics & Plagiarism (8 June 2010)
11. Multilevel Analysis (7 February 2010)
12. STATA software for General & Advanced Analysis (20 and 21 January 2010)
13. End Note X3 software (7-9 October 2009)
14. Qualitative Studies (2 and 3 January 2009)
15. Strategic Approach (1 and 2 July 2008)
16. STATA software for Meta-analysis (2 and 3 January 2008)
17. Evidence Based Medicine (EBM) (5-8 April 2006)
18. Geographic Information Systems (GIS) in Epidemiologic Studies (1 March 2006)
19. Case Report Studies (5-7 December 2004)
20. Concept Mapping (13 and 14 October 2004)
21. Validity and Reliability of a Questionnaire (13 and 14 October 2004)
22. Writing a scientific paper (20-22 October 2003)
23. Focus Group Discussion (25 December 2002)
24. Survival Analysis (21 and 22 August 2002)
25. Sampling and Calculating Sample Size (15-18 April 2002)

15. TEACHING EXPERIENCE

15.1 SUMMER SCHOOLS

1. The 5th Parkinson's Disease Summer School for Healthcare Students, Montreal, Canada (16-25 September 2013)

15.2 WORKSHOPS

1. SMILE-SPSS Workshop, Stockholm, Sweden (23-24 April 2014)
2. Publication Strategy in Biomedical Journals (December 2011)
3. Proposal Appraisal in Medical Researches (December 2011)
4. Search Strategy in Biomedical Studies (November 2011)
5. Clinical Trial Registration (October 2010)
6. Training biostatistical referees and reviewers (October 2010, December 2010, March 2011, April 2011, May 2011, June 2011, November 2011)
7. Advanced Biostatistics (September 2010)
8. Study Designing (July 2010)
9. Preparing a Standard Proposal in Medical Researches (July 2008, June 2010)
10. Writing a scientific paper (June 2008, October 2008, November 2011)
11. Case report studies (June 2008, March 2010)
12. Preparing a Standard Questionnaire in Medical Researches (September 2005, May 2008)
13. SPSS software (August 2005, November 2008, March-August 2011)
14. Sampling and Calculating Sample Size (December 2003, September 2006, February 2012)
15. General Research Methodology (May 2002- April 2011)

16. SUPERVISION, MENTORSHIP

16.1 CO-SUPERVISION

1. **Sarehnaz Aghili**, '*Prevalence and associated comorbidities of peripheral neuropathy in the adult population of Tehran aged >40 years*', MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2016)
2. **Alaleh Zamiri**, '*Evaluation of the non-communicable comorbidities and risk factors of parkinsonism in the adult population of Tehran in the year 2011*', MPH. Degree, Tehran University of Medical Sciences, Tehran, Iran (2016)
3. **Mahdyeh Shafiei Sabet**, '*Estimation of the prevalence of headaches and migraine headache in adult population of Tehran urban area aged >40 years*'. MPH. Degree, Tehran University of Medical Sciences, Tehran, Iran (2016)
4. **Mahdyeh Shafiei Sabet**, '*Restless legs syndrome in patients with Parkinson's disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status*'. MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2015)
5. **Mahshid Soori**, '*Prevalence of restless legs syndrome (RLS) in the adult population of Tehran aged >40 years*', MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2015)
6. **Farzaneh Farhadi**, '*Reliability and validity of the Persian version of the fatigue severity scale in idiopathic Parkinson's disease patients*', MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2015)
7. **Nader Naderi**, '*Psychometric study of the Persian short-form eight-item Parkinson's disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL)*', MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2015)
8. **Hasti Hadizadeh**, '*Cross-cultural validity, reliability, and psychometric properties of the Persian version of the scales for outcomes in Parkinson's disease-psychosocial questionnaire*', MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2015)
9. **Azin Shafiei Sabet**, '*Hyperchogenicity of substantia nigra for differential diagnosis of Parkinson's disease: A meta-analysis*', MD. Degree, Iran University of Medical Sciences, Tehran, Iran (2015)
10. **Farshad Sheybaee-Moghaddam**, '*Prevalence of plagiarism in the abstracts accepted for presentation in the 1st and 2nd Students International Conference on Biomedical and Interdisciplinary Research (SICOBAIR) in 2009 and 2011*', MD. Degree, Tehran University of Medical Sciences, Tehran, Iran (2014)
11. **Ladan Ghazi**, '*Evaluation of nutritional status among Iranian Parkinson's disease patients*', MSc. Degree, Karolinska Institutet, Stockholm, Sweden (2012)

17. SCIENTIFIC REVIEWER

17.1 PEER-REVIEWED JOURNALS

1. JAMA Neurology
2. Neurology (x9)
3. Journal of Neurology, Neurosurgery, and Psychiatry (x4)
4. Alzheimer's & Dementia: The Journal of the Alzheimer's Association
5. Movement Disorders (x2)
6. Parkinsonism & Related Disorders

7. Parkinson's Disease (x3)
8. NeuroImage
9. Neurotoxicology
10. BMC Neurology (x2)
11. Brain and Behavior
12. Brain Imaging and Behavior
13. Journal of the Neurological Sciences (x3)
14. Clinical Neurology & Neurosurgery (x17)
15. Journal of Alzheimer's Disease (x2)
16. Journal of Neurology
17. Neurological Sciences (x7)
18. Basic & Clinical Neuroscience
19. Neurodegenerative Disease Management
20. Neuropsychiatric Disease and Treatment
21. Nordic Journal of Psychiatry
22. Neurology, Psychiatry and Brain Research
23. International Journal of Geriatric Psychiatry
24. BMC Geriatrics
25. Disability and Rehabilitation (x2)
26. BMJ Open
27. PLOS ONE (x4)
28. Scientific Reports
29. Value in Health (x4)
30. Drugs - Real World Outcomes
31. Clinical and Experimental Hypertension
32. Journal of Critical Care (x2)
33. Journal of Research in Medical Sciences
34. Cardiovascular Journal of Africa (x7)
35. BMC Gastroenterology
36. Mycopathologia
37. Undersea & Hyperbaric Medicine
38. Journal of Thrombosis & Haemostasis
39. Journal of Transcultural Nursing
40. Archives of Medical Research
41. Medical Decision Making
42. International Journal of Preventive Medicine
43. World Journal of Nephrology
44. Infectious Agents & Cancer
45. Head & Face Medicine
46. Medical Journal of The Islamic Republic of Iran (x13)
47. Iranian Red Crescent Medical Journal (x5)
48. Journal of Iran University of Medical Sciences
49. Journal of Zanjan University of Medical Sciences
50. Razi Journal of Medical Sciences
51. Thrita Journal of Medical Sciences

17.2 CONFERENCES

1. The 11th Iran Medical Education Conference, Tehran, Iran, (30 April-2 May 2010)

2. The 11th National Medical Students' Research Congress, Bandar Abbas, Iran, (20-23 April 2010)
3. The 8th National Medical Students' Research Congress, Shiraz, Iran, (23-25 May 2007)
4. The 7th National Medical Students' Research Congress, Tehran, Iran, (30 May-1 June 2006)

18. TECHNICAL SKILLS

Software knowledge including all standard of Microsoft office software, image processing, statistical analysis and graphs generation, using **SPSS, End Note, G-Power, SIMCA, MODDE, Stata, SAS, Mplus, R**

19. LANGUAGE SKILLS

1. **Persian** (Native)
2. **English** (Fluent)
 - TOEFL iBT (2011): Total 95, Reading 25, Listening 25, Speaking 23, Writing 22
 - IELTS Academic (2017): Total 8, Reading 8.5, Listening 8.5, Speaking 8, Writing 7.5
 - Iran Language Institute (ILI): 13 semesters
3. **French** (Intermediate)
 - French Assessment Interview: Intermediate 3
 - Iran Language Institute (ILI): 9 semesters
4. **Swedish** (Beginner)

20. HOBBIES, SPORTS

1. Jogging
2. Basketball
3. Swimming
4. Ping-Pong
5. Persian Calligraphy

21. REFERENCES

1. **Ronald B. Postuma** *MD MSc*
Associate Professor, Movement Disorders Specialists, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada
Email: ron.postuma@mcgill.ca
2. **Alain Dagher** *MD MSc*
Professor, Movement Disorders Specialists, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
Email: alain.dagher@mcgill.ca
3. **Johan Lökk** *MD PhD*

Professor, Head physician, Head of the department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden

Department of Neurobiology, Care Sciences & Society (NVS), Karolinska Institutet, Stockholm, Sweden

Email: joan.lokk@karolinska.se

4. **Maria Eriksson** *MD PhD*

Professor, Head of the Department of Neurobiology, Care Sciences & Society (NVS), Karolinska Institutet, Stockholm, Sweden

Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden

Email: maria.eriksson@ki.se